CIN-107
DrugCIN-107 tablets by mouth once daily
Other names: baxdrostat
NCT Number: NCT04519658
This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of CIN-107 as compared to placebo after 12 weeks of treatment in patients with treatment-resistant hypertension (rHTN).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
CinCor Site 16, Birmingham, Alabama, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CIN-107 tablets by mouth once daily
Other names: baxdrostat
placebo tablets by mouth once daily
Time frame: 12 weeks
Time frame: 12 weeks
Time frame: 12 weeks
CinCor Pharma, Inc.
Industry
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension (rHTN)
Acronym: BrigHTN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06034743
Cardiovascular Diseases, Hypertension
Saraland, Alabama, United States
View Trial DetailsNCT07589881
Behavior, Female Urogenital Diseases
Sant Joan Despí, Barcelona, Spain
View Trial DetailsNCT06344104
Cardiovascular Diseases, Hypertension
Bahía Blanca, Argentina
View Trial DetailsNCT05464849
Arterial Hypertension, Cardiovascular Diseases
Rio de Janeiro, Brazil
View Trial Details